The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Novo’s hemophilia A preventive therapy, alongside positive opinions for seven additional medicines and 11 label expansions. The CHMP’s monthly outcome list signals regulators’ readiness to expand treatment options across multiple therapeutic areas in the EU. CHMP recommendations include new ovarian cancer therapies and a potential first oral option for hidradenitis suppurativa, according to the agenda items summarized by the publication. If adopted by the European Commission, these opinions could broaden access for patients across oncology and chronic inflammatory disease. For companies operating in Europe, CHMP opinions are a key step in the approval timeline and influence launch planning and pricing negotiations.